Schrödinger Revises 2025 Software Growth Forecast to 8%-13% Due to Pharma Scale-Up Delays and Emphasis on Operational Efficiency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy SDGR?
Source: SeekingAlpha
Management Overview: CEO Ramy Farid reported a 54% increase in total revenue to $54 million for Q3 2025, driven by strong demand for software and drug discovery solutions, while adjusting software revenue growth guidance to 8%-13% due to delays in pharma scale-up opportunities.
Financial Performance: The company achieved software revenue of $40.9 million and drug discovery revenue of $13.5 million, with a net loss of $33 million. Operating expenses decreased, and cash reserves stood at $401 million as of September 30.
Strategic Focus: Schrödinger is shifting its strategy away from advancing internal discovery programs independently, emphasizing early-stage discovery partnerships and operational efficiency to navigate current market challenges.
Analyst Sentiment: Analysts expressed concerns about customer acquisition and growth visibility, noting a cautious tone from management regarding near-term uncertainties, while maintaining optimism about long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SDGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SDGR
Wall Street analysts forecast SDGR stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 12.340
Low
18.00
Averages
21.83
High
25.00
Current: 12.340
Low
18.00
Averages
21.83
High
25.00
About SDGR
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Schrodinger Inc's Strategic Shift to AI and Hosted Contracts
- Strategic Shift: Schrodinger Inc aims to transition 75% of its software contracts to hosted models within three years, responding to customer demand for cloud solutions, which will help expand its user base and enhance market competitiveness.
- AI Integration Partnership: The company is collaborating with AI firms like Anthropic to integrate AI features into its platform, which is expected to improve user efficiency, thereby enhancing customer satisfaction and loyalty.
- Financial Performance: In Q4 2025, Schrodinger reported revenue of $87.2 million, a 1.2% year-over-year decline, yet exceeding the forecast of $83.65 million, with drug discovery revenue more than doubling to $18 million, indicating strong performance in drug development.
- Partnership Development: Schrodinger's partnership with Eli Lilly allows it to integrate the AI-driven TuneLab platform into its cloud-based LiveDesign platform, further enhancing efficiency and cost-effectiveness for biotech companies in drug development.
See More
Schrödinger Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On April 16, 2026, Schrödinger granted 4,253 restricted stock units (RSUs) to four new employees, aimed at attracting talent and enhancing retention, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Grant Conditions: These RSUs are awarded under the company's 2021 Inducement Equity Incentive Plan, with 25% vesting after 12 months of continuous service, and the remainder vesting in equal annual installments over the subsequent three years, ensuring long-term employee commitment.
- Company Background: Founded in 1990, Schrödinger has approximately 800 employees and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial companies, showcasing significant market potential and technological advantages.
- Global Operations: Operating from 15 locations worldwide, Schrödinger's software platform, built on over 30 years of R&D investment, is licensed by various institutions, further solidifying its leadership in molecular design and drug development.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On March 14, 2026, Schrödinger granted a newly hired employee a stock option to purchase 1,950 shares at an exercise price of $12.51 per share, aligning with Nasdaq Listing Rule to attract talent and enhance employee loyalty.
- Restricted Stock Units: The company also awarded 4,375 restricted stock units (RSUs) to two new employees, reflecting the company's commitment to investing in its workforce under the 2021 Inducement Equity Incentive Plan.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after the first 12 months, followed by monthly or yearly installments, ensuring a long-term incentive for employee retention and service.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on molecular discovery through its computational platform, serving the biotechnology and pharmaceutical sectors, showcasing strong market competitiveness and technological prowess.
See More
Schrödinger Reports Strong Q4 2025 Earnings with Strategic Transition to Hosted Model
- Significant Revenue Growth: Schrödinger reported total revenue of $256 million for 2025, reflecting a 23% increase despite challenges from tight pharma budgets and biotech capital markets, underscoring the company's strong market position in molecular discovery.
- Software Business Performance: The software segment generated $199.5 million in revenue, an 11% increase year-over-year, while drug discovery revenue more than doubled to $56.4 million, indicating success in new product launches and customer expansion.
- Strategic Transition Progress: Schrödinger is shifting towards a primarily hosted licensing model, with expectations for 10% to 15% growth in annual contract value (ACV) for 2026, aiming for substantial growth in the coming years.
- Cost Control Effectiveness: Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, as the company implemented cost reduction initiatives, enhancing confidence in future profitability.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On February 13, 2026, Schrödinger granted non-statutory stock options to purchase 9,600 shares at an exercise price of $11.40 per share, aligning with the closing price, aimed at attracting top talent to the company.
- Restricted Stock Units: The company also awarded 18,250 restricted stock units (RSUs) to eight new employees, conducted under the 2021 Inducement Equity Incentive Plan, reflecting the company's commitment to incentivizing new hires.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after 12 months of continuous service, followed by monthly or yearly installments, ensuring employee retention and enhancing company stability.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial sectors, showcasing strong market competitiveness and technological prowess.
See More
Schrodinger Inc's Strategic Shift to AI and Hosted Contracts
- Strategic Shift: Schrodinger Inc aims to transition 75% of its software contracts to hosted models within three years, responding to customer demand for cloud solutions, which will help expand its user base and enhance market competitiveness.
- AI Integration Partnership: The company is collaborating with AI firms like Anthropic to integrate AI features into its platform, which is expected to improve user efficiency, thereby enhancing customer satisfaction and loyalty.
- Financial Performance: In Q4 2025, Schrodinger reported revenue of $87.2 million, a 1.2% year-over-year decline, yet exceeding the forecast of $83.65 million, with drug discovery revenue more than doubling to $18 million, indicating strong performance in drug development.
- Partnership Development: Schrodinger's partnership with Eli Lilly allows it to integrate the AI-driven TuneLab platform into its cloud-based LiveDesign platform, further enhancing efficiency and cost-effectiveness for biotech companies in drug development.
See More
Schrödinger Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On April 16, 2026, Schrödinger granted 4,253 restricted stock units (RSUs) to four new employees, aimed at attracting talent and enhancing retention, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Grant Conditions: These RSUs are awarded under the company's 2021 Inducement Equity Incentive Plan, with 25% vesting after 12 months of continuous service, and the remainder vesting in equal annual installments over the subsequent three years, ensuring long-term employee commitment.
- Company Background: Founded in 1990, Schrödinger has approximately 800 employees and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial companies, showcasing significant market potential and technological advantages.
- Global Operations: Operating from 15 locations worldwide, Schrödinger's software platform, built on over 30 years of R&D investment, is licensed by various institutions, further solidifying its leadership in molecular design and drug development.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On March 14, 2026, Schrödinger granted a newly hired employee a stock option to purchase 1,950 shares at an exercise price of $12.51 per share, aligning with Nasdaq Listing Rule to attract talent and enhance employee loyalty.
- Restricted Stock Units: The company also awarded 4,375 restricted stock units (RSUs) to two new employees, reflecting the company's commitment to investing in its workforce under the 2021 Inducement Equity Incentive Plan.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after the first 12 months, followed by monthly or yearly installments, ensuring a long-term incentive for employee retention and service.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on molecular discovery through its computational platform, serving the biotechnology and pharmaceutical sectors, showcasing strong market competitiveness and technological prowess.
See More
Schrödinger Reports Strong Q4 2025 Earnings with Strategic Transition to Hosted Model
- Significant Revenue Growth: Schrödinger reported total revenue of $256 million for 2025, reflecting a 23% increase despite challenges from tight pharma budgets and biotech capital markets, underscoring the company's strong market position in molecular discovery.
- Software Business Performance: The software segment generated $199.5 million in revenue, an 11% increase year-over-year, while drug discovery revenue more than doubled to $56.4 million, indicating success in new product launches and customer expansion.
- Strategic Transition Progress: Schrödinger is shifting towards a primarily hosted licensing model, with expectations for 10% to 15% growth in annual contract value (ACV) for 2026, aiming for substantial growth in the coming years.
- Cost Control Effectiveness: Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, as the company implemented cost reduction initiatives, enhancing confidence in future profitability.
See More
Investment Opportunities in Oversold Healthcare Stocks
- Oversold Stocks Overview: The healthcare sector's oversold stocks present investors with opportunities to buy undervalued companies, particularly those with a Relative Strength Index (RSI) below 30, indicating potential short-term rebounds.
- Schrödinger Inc Performance: Schrödinger (NASDAQ:SDGR) has seen its stock price fall approximately 28% over the past month, currently holding an RSI of 29.9 and a 52-week low of $11.15, although shares rose 1.6% to $11.81 on Wednesday, indicating some rebound potential.
- Edge Stock Ratings: With a momentum score of 2.78, Schrödinger's performance is relatively weak in the market, yet its oversold status may attract investor interest, especially during market recoveries.
- Industry Dynamics Analysis: As the healthcare sector experiences volatility, investors should focus on the potential rebound opportunities of oversold stocks, particularly those with RSIs near or below 30, to capitalize on gains when the market stabilizes.
See More
Schrödinger Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On February 13, 2026, Schrödinger granted non-statutory stock options to purchase 9,600 shares at an exercise price of $11.40 per share, aligning with the closing price, aimed at attracting top talent to the company.
- Restricted Stock Units: The company also awarded 18,250 restricted stock units (RSUs) to eight new employees, conducted under the 2021 Inducement Equity Incentive Plan, reflecting the company's commitment to incentivizing new hires.
- Vesting Schedule: Both the stock options and RSUs vest over four years, with 25% vesting after 12 months of continuous service, followed by monthly or yearly installments, ensuring employee retention and enhancing company stability.
- Company Overview: Founded in 1990, Schrödinger employs approximately 800 people and focuses on transforming molecular discovery through its computational platform, serving biotechnology, pharmaceutical, and industrial sectors, showcasing strong market competitiveness and technological prowess.
See More
